Showing results (801-810 of 3,472) with videos related to

Sort By:
Pageof 348
Clinical Pharmacokinetics|September 15, 2025
Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney DiseaseElias John Elenjickal, Thomas A Mavrakanas, Ari Gritsas, et al.
Clinical Pharmacokinetics|June 14, 2025
Determining the Optimal Dosing of Methyldopa in Pregnancy-Induced Hypertension Using PBPK-PD ModelingXinyang Liu, Wei Wang, Jinying Zhu, et al.
Clinical Pharmacokinetics|June 23, 2025
Pharmacokinetics of Binimetinib in Participants with Hepatic ImpairmentJoseph Piscitelli, Erik Hahn, Lance Wollenberg, et al.
Clinical Pharmacokinetics|June 1, 2025
Utilizing Opportunistic Computed Tomography Imaging to Refine Lean Body Weight Estimates in Patients with ObesityRadin Alikhani, Steven Horbal, Amy E Rothberg, et al.
Clinical Pharmacokinetics|May 28, 2025
Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary HypertensionYu Lin, Yuanqi Su, Zhongjie Cheng, et al.
Clinical Pharmacokinetics|February 23, 2024
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy VolunteersBrit S Rohr, Evelyn Krohmer, Kathrin I Foerster, et al.
Clinical Pharmacokinetics|March 15, 2024
Clinical Pharmacokinetics and Pharmacodynamics of NaloxoneTeijo I Saari, John Strang, Ola Dale
Clinical Pharmacokinetics|March 15, 2024
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel DiseaseNanja C Bevers, Ron J Keizer, Dennis R Wong, et al.
Clinical Pharmacokinetics|March 9, 2024
Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban TherapyYi Ma, Zaiwei Song, Xinya Li, et al.
Clinical Pharmacokinetics|July 11, 2024
Machine Learning Approach in Dosage Individualization of Isoniazid for TuberculosisBo-Hao Tang, Xin-Fang Zhang, Shu-Meng Fu, et al.
Pageof 348